ACT Brief: Site Data Quality Takes Priority, Merck Expands AI Discovery Efforts, and Gilead Advances Cell Therapy Strategy

In today’s ACT Brief, we examine how site-level data capture is becoming central to trial execution, how Merck and Mayo Clinic are scaling AI-driven discovery, and how Gilead’s latest acquisition strengthens its position in cell therapy for multiple myeloma.